Fibrinogen Antibody

Immunocytochemistry/ Immunofluorescence: Fibrinogen Antibody [NBP2-80414]

Immunocytochemistry/Immunofluorescence: Fibrinogen Antibody [NBP2-80414] - Staining Fibrinogen in NIH-3T3 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100/PBS.

Immunocytochemistry/ Immunofluorescence: Fibrinogen Antibody [NBP2-80414] -

Fibrinogen deposition after ischemia. (A) Fibrinogen immunostaining (green) in the peri‐infarct areas at 1, 3, 7, and 14 days after MCAO and uninjured mice. Scale bar, 50 μm. (B) Quantification of fibrinogen immunoreactivity in the peri‐infarct areas per area. (C) Scheme illustrating MCAO on ancrod‐administered mice. (D) Enzyme‐linked immunosorbent assay quantification of fibrinogen. (E) Nestin (red) and fibrinogen (green) immunostainings in the peri‐infarct areas 3 days after MCAO. White arrowheads show the colocalization of nestin and fibrinogen. Scale bar, 25 μm. (F) GFAP (red) and fibrinogen (green) immunostainings in the peri‐infarct areas 3 days after MCAO. White arrowheads show the colocalization of GFAP and fibrinogen. Scale bar, 25 μm. (G) Iba1 (red) and fibrinogen (green) immunostainings in the peri‐infarct areas 3 days after MCAO. White arrowheads show the colocalization of Iba1 and fibrinogen. Scale bar, 25 μm. N = 6 mice. Data are presented as mean +/- SEM, one‐way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36756722), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: Fibrinogen Antibody [NBP2-80414] -

Fibrinogen inhibits remyelination after MCAO and disrupts OPC differentiation by activating ACVR1. (A) MBP (red) and fibrinogen (green) immunostaining in the peri‐infarct areas 7 days after MCAO. Scale bar, 50 μm. (B) Quantification of MBP immunoreactivity in the peri‐infarct areas per area. N = 6 mice. (C) MBP mRNA expression. N = 6 mice. (D) Transmission electron microscope analysis was performed on the peri‐infarct areas. Scale bar, 1 μm (top), 0.5 μm (bottom). (E) Quantification of the myelinated axons (% of total axons). N = 6 mice. (F) Volcano plot of differentially expressed genes. Red points represent upregulated genes, blue points represent downregulated genes, and gray points represent the unchanged genes. (G) Heatmap of differentially expressed genes in untreated OPCs and fibrinogen‐treated OPCs. N = 3 per group. (H) The verification of ACVR1 mRNA expression. N = 6 per group. Data are presented as mean +/- SEM, one‐way ANOVA, or unpaired Student's t‐test, ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36756722), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: Fibrinogen Antibody [NBP2-80414] -

Fibrinogen deposition after ischemia. (A) Fibrinogen immunostaining (green) in the peri‐infarct areas at 1, 3, 7, and 14 days after MCAO and uninjured mice. Scale bar, 50 μm. (B) Quantification of fibrinogen immunoreactivity in the peri‐infarct areas per area. (C) Scheme illustrating MCAO on ancrod‐administered mice. (D) Enzyme‐linked immunosorbent assay quantification of fibrinogen. (E) Nestin (red) and fibrinogen (green) immunostainings in the peri‐infarct areas 3 days after MCAO. White arrowheads show the colocalization of nestin and fibrinogen. Scale bar, 25 μm. (F) GFAP (red) and fibrinogen (green) immunostainings in the peri‐infarct areas 3 days after MCAO. White arrowheads show the colocalization of GFAP and fibrinogen. Scale bar, 25 μm. (G) Iba1 (red) and fibrinogen (green) immunostainings in the peri‐infarct areas 3 days after MCAO. White arrowheads show the colocalization of Iba1 and fibrinogen. Scale bar, 25 μm. N = 6 mice. Data are presented as mean +/- SEM, one‐way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36756722), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: Fibrinogen Antibody [NBP2-80414] -

miR‐128‐3p mediates OPC differentiation by targeting fibrinogen‐BMP signaling. (A) Immunoblot analysis for Lef1 and P‐Smad1/5 after MCAO treated with fibrinogen or ancrod. (B and C) Quantification of Lef1 and P‐Smad1/5 expression. N = 6 mice. (D) Id2 (red) and fibrinogen (green) immunostaining. Scale bar, 50 μm. (E) Quantification of Id2 immunoreactivity. N = 6 mice. (F) Comparison of miRNAs expression in fibrinogen‐treated OPCs and untreated OPCs by miRNAs sequencing. N = 3 per group. (G) Venn diagram displaying miR‐128‐3p computationally predicted targets by three different prediction algorithms: targetScan, starbase, and miRWalk. (H) The verification of miR‐128‐3p relative expression by qRT‐PCR analysis. N = 6 per group. Data are presented as mean +/- SEM, one‐way ANOVA or unpaired Student's t‐test, **p < 0.01, ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36756722), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: Fibrinogen Antibody [NBP2-80414] -

Fibrinogen deposition after ischemia. (A) Fibrinogen immunostaining (green) in the peri‐infarct areas at 1, 3, 7, and 14 days after MCAO and uninjured mice. Scale bar, 50 μm. (B) Quantification of fibrinogen immunoreactivity in the peri‐infarct areas per area. (C) Scheme illustrating MCAO on ancrod‐administered mice. (D) Enzyme‐linked immunosorbent assay quantification of fibrinogen. (E) Nestin (red) and fibrinogen (green) immunostainings in the peri‐infarct areas 3 days after MCAO. White arrowheads show the colocalization of nestin and fibrinogen. Scale bar, 25 μm. (F) GFAP (red) and fibrinogen (green) immunostainings in the peri‐infarct areas 3 days after MCAO. White arrowheads show the colocalization of GFAP and fibrinogen. Scale bar, 25 μm. (G) Iba1 (red) and fibrinogen (green) immunostainings in the peri‐infarct areas 3 days after MCAO. White arrowheads show the colocalization of Iba1 and fibrinogen. Scale bar, 25 μm. N = 6 mice. Data are presented as mean +/- SEM, one‐way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36756722), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: Fibrinogen Antibody [NBP2-80414] -

Fibrinogen deposition after ischemia. (A) Fibrinogen immunostaining (green) in the peri‐infarct areas at 1, 3, 7, and 14 days after MCAO and uninjured mice. Scale bar, 50 μm. (B) Quantification of fibrinogen immunoreactivity in the peri‐infarct areas per area. (C) Scheme illustrating MCAO on ancrod‐administered mice. (D) Enzyme‐linked immunosorbent assay quantification of fibrinogen. (E) Nestin (red) and fibrinogen (green) immunostainings in the peri‐infarct areas 3 days after MCAO. White arrowheads show the colocalization of nestin and fibrinogen. Scale bar, 25 μm. (F) GFAP (red) and fibrinogen (green) immunostainings in the peri‐infarct areas 3 days after MCAO. White arrowheads show the colocalization of GFAP and fibrinogen. Scale bar, 25 μm. (G) Iba1 (red) and fibrinogen (green) immunostainings in the peri‐infarct areas 3 days after MCAO. White arrowheads show the colocalization of Iba1 and fibrinogen. Scale bar, 25 μm. N = 6 mice. Data are presented as mean +/- SEM, one‐way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36756722), licensed under a CC-BY license. Not internally tested by Novus Biologicals.